Novoste Parrying Drug-Coated Stents With Planned Indications For Beta-Cath
This article was originally published in The Gray Sheet
Executive Summary
Novoste will rely on supplemental indications unaddressed by drug-coated stent developers to increase adoption of its Beta-Cath vascular brachytherapy system.
You may also be interested in...
Cardiologist Group Lobbying For Medicare Fee Schedule Updates In 2003
CMS' Nov. 1 physician's fee schedule establishes a procedure-specific fee code for catheter placement during cardiac brachytherapy (CPT code 92974)
Cardiologist Group Lobbying For Medicare Fee Schedule Updates In 2003
CMS' Nov. 1 physician's fee schedule establishes a procedure-specific fee code for catheter placement during cardiac brachytherapy (CPT code 92974)
Merit Margin Growth, Cath-Lab Strength Aid Stock's Momentum In August
Merit Medical stock continued to build momentum in August following the July release of strong second quarter financial results that reflect both improving business fundamentals like gross margins and competitive strength in its core cath-lab accessory market.